menu
    • menu
    [{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ASHA-624","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Asha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"The ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"ASHA-624","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Asha Therapeutics \/ The ALS Association","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ The ALS Association"}]

    Find Clinical Drug Pipeline Developments & Deals by Asha Therapeutics

    Menu

    Asha Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asha Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Asha Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASHA-624

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : The ALS Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Asha Receives ALS Grant for Novel SARM1 Inhibitor and Expands Advisory Board

                            Details : The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS).

                            Brand Name : ASHA-624

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : ASHA-624

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : The ALS Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asha Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Asha Therapeutics

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASHA-624

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Asha Nominates ASHA-624 as a Novel Glue Therapy for Amyotrophic Lateral Sclerosis

                            Details : ASHA-624 is a first-in-class, novel intra-molecular glue compound that exploits the normal biology of SARM1. It is being evaluated for the treatment of amyotrophic lateral sclerosis.

                            Brand Name : ASHA-624

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2024

                            Lead Product(s) : ASHA-624

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth